Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR vs DELCOBESE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Pseudoephedrine sulfate is an alpha-adrenergic receptor agonist causing vasoconstriction.
Selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking the serotonin transporter (SERT). Additionally, it has a unique property of acting as an agonist at the 5-HT2C receptor, which may contribute to its anorectic effects.
Relief of nasal and non-nasal symptoms of seasonal allergic rhinitis,Relief of nasal congestion associated with allergic rhinitis or common cold
Chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia)
One tablet (desloratadine 5 mg/pseudoephedrine sulfate 240 mg) orally once daily.
Initial dose: 0.5 mg subcutaneously once weekly for 4 weeks, then increase to 1 mg once weekly for 4 weeks, then maintain at 2 mg once weekly. Titrate based on glycemic control up to 2 mg weekly.
Desloratadine: 27 hours (terminal); pseudoephedrine sulfate: 5-8 hours (terminal, dependent on urine p H).
12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours with Cr Cl <30 m L/min).
Desloratadine is metabolized to 3-hydroxydesloratadine via CYP2C8 and CYP3A4. Pseudoephedrine is partially metabolized in the liver by N-demethylation.
Primarily metabolized by cytochrome P450 (CYP) 2D6 with minor contributions from CYP3A4 and CYP2C19. Active metabolite N-desmethyl lorcaserin is formed via CYP2D6.
Desloratadine: 41% urine (metabolites), 47% feces (metabolites); pseudoephedrine sulfate: 70-90% renal (unchanged), 1% biliary.
Primarily renal (60-70% unchanged) with 20-30% fecal via biliary elimination; less than 5% metabolized.
Desloratadine: 83-87% bound (primarily albumin); pseudoephedrine sulfate: minimal binding, ~20% bound.
95% bound to albumin and alpha-1-acid glycoprotein.
Desloratadine: ~16.8 L/kg (high Vd, extensive tissue distribution); pseudoephedrine sulfate: ~2.6-3.5 L/kg (moderate Vd).
0.3-0.4 L/kg; indicates moderate distribution to extracellular fluid and well-perfused tissues.
Desloratadine: 76% (oral); pseudoephedrine sulfate: ~100% (extended-release formulation).
Oral: 40-50% (first-pass effect); Subcutaneous: 70-80%; IV: 100%.
Contraindicated in GFR < 30 m L/min. For GFR 30-59 m L/min: not recommended due to lack of data. For GFR ≥ 60 m L/min: no adjustment needed.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m2). Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease.
No specific Child-Pugh based recommendations. Use with caution in severe hepatic impairment; desloratadine clearance reduced.
No dose adjustment required for mild hepatic impairment (Child-Pugh class A). Not recommended for moderate or severe hepatic impairment (Child-Pugh class B or C) due to lack of data.
Not approved for pediatric patients; safety and efficacy not established in children <12 years. For ≥12 years: same as adult.
Not approved for use in pediatric patients under 18 years of age. Safety and efficacy have not been established.
Use with caution due to increased sensitivity, risk of CNS effects, and potential renal impairment. Consider starting at lower doses; avoid in patients with severe renal impairment.
No specific dose adjustment required; initiate at 0.5 mg subcutaneously once weekly and titrate cautiously due to potential for renal function decline and increased sensitivity. Monitor renal function and consider dose reduction if e GFR declines.
None.
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS - Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. Monitor for worsening and emergence of suicidal thoughts and behaviors. DELCOBESE is not approved for use in pediatric patients.
Severe hypertension and/or tachycardia,Cardiovascular disease including ischemic heart disease and arrhythmias,Increased intraocular pressure,Diabetes mellitus,Thyroid dysfunction,Prostatic hypertrophy/urinary retention,Renal impairment,Seizure disorders,Use in elderly patients
Risk of serotonin syndrome or neuroleptic malignant syndrome when coadministered with other serotonergic drugs. Potential for pulmonary hypertension. Monitor for valvular heart disease (5-HT2B receptor agonist activity). Caution in patients with renal impairment (e GFR <30 m L/min). Avoid in pregnancy (potential for fetal harm).
Hypersensitivity to desloratadine, pseudoephedrine, or any component,Severe hypertension,Coronary artery disease,Use of MAO inhibitors within 14 days,Narrow-angle glaucoma,Urinary retention,Severe renal impairment (Cr Cl <30 m L/min)
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI. Known hypersensitivity to DELCOBESE or any component. Severe renal impairment (e GFR <30 m L/min) or end-stage renal disease. History of pulmonary hypertension. Pregnancy.
Avoid alcohol as it may increase sedative effects. Limit or avoid caffeine-containing foods/drinks (coffee, tea, soda, chocolate) to reduce risk of nervousness, insomnia, and tachycardia. No specific food interactions with desloratadine; pseudoephedrine is not significantly affected by food.
Avoid grapefruit and grapefruit juice which inhibits CYP3A4 metabolism increasing DELCOBESE levels. Avoid high-fat meals as they increase absorption and risk of adverse effects. Limit alcohol to no more than 1 drink per day due to additive CNS depression. Ensure adequate hydration to prevent constipation.
Desloratadine: no human data, animal studies show no evidence of harm; risk cannot be excluded. Pseudoephedrine: associated with increased risk of gastroschisis in first trimester; possible uterine vasoconstriction in second/third trimester. Overall, avoid in first trimester; use only if benefit outweighs risk in second/third trimester.
DELCOBESE is contraindicated in pregnancy. First trimester exposure is associated with increased risk of major congenital malformations, particularly neural tube defects, cardiac anomalies, and cleft palate. Second and third trimester exposure can cause fetal growth restriction, oligohydramnios, and neonatal renal impairment. There is a dose-dependent risk of pregnancy loss.
Desloratadine: low excretion into breast milk; M/P ratio not established. Pseudoephedrine: small amounts in milk; peak milk concentration at 2-4 hours; M/P ratio 1.7-3.5. May cause irritability or sleep disturbance in infants; reduce breast milk production. Not recommended during breastfeeding.
Excretion into breast milk is unknown; due to potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during therapy and for at least 1 week after the last dose. No M/P ratio data available.
No pharmacokinetic data in pregnancy; standard dosing not recommended due to risk profile. Use only if clearly needed and under medical supervision.
Do not use in pregnancy. No dosing adjustment recommendations exist as the drug is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) are not applicable.
Desloratadine is a long-acting antihistamine; pseudoephedrine sulfate is a nasal decongestant. The 24-hour formulation provides extended relief. Use with caution in patients with hypertension, hyperthyroidism, or benign prostatic hyperplasia. Avoid in narrow-angle glaucoma. Monitor for insomnia and nervous system stimulation. May cause dry mouth and urinary retention.
DELCOBESE is a novel synthetic cannabinoid receptor antagonist/inverse agonist (CB1R) approved for weight management. Monitor for psychiatric adverse effects (depression, suicidal ideation) especially during first 3 months. Avoid in patients with history of seizures due to lowered seizure threshold. Titrate dose slowly: start at 5 mg BID, increase to 10 mg BID after 4 weeks if tolerated. Discontinue if no 5% weight loss at 12 weeks. Use contraception in women of childbearing potential due to teratogenicity. Check liver function tests monthly for first 6 months due to rare hepatotoxicity.
Take one tablet daily with a full glass of water; do not crush or chew.,Avoid taking with other sympathomimetic amines (e.g., pseudoephedrine, phenylephrine) to prevent excessive cardiovascular stimulation.,May cause drowsiness; avoid driving or operating heavy machinery until you know how the medication affects you.,Limit caffeine intake to reduce additive stimulant effects.,Do not use if you have severe hypertension, coronary artery disease, or are taking MAOIs currently or within past 14 days.
Take exactly as prescribed; do not exceed 20 mg per day.,May cause dizziness or drowsiness; avoid driving until you know how this drug affects you.,Report any new or worsening depression, anxiety, or thoughts of self-harm immediately.,Use effective contraception during treatment and for 1 month after stopping.,Avoid alcohol and grapefruit juice as they may increase side effects.,Inform your doctor if you have a history of seizures or liver disease.,Do not stop suddenly; taper under medical supervision to avoid withdrawal symptoms.,Maintain a reduced-calorie diet and exercise program for best results.
"Ketazolam, a benzodiazepine, can cause central nervous system (CNS) depression. Desloratadine, a nonsedating antihistamine, has a low potential for CNS depression at therapeutic doses. However, when combined with benzodiazepines, the risk of additive CNS depressant effects increases, potentially leading to excessive sedation, dizziness, and impaired psychomotor function. This interaction is particularly relevant in patients with hepatic impairment or those taking higher doses of either drug."
"Paroxetine, a potent inhibitor of CYP2D6, can increase plasma concentrations of desloratadine, which is partially metabolized by CYP2D6. This elevation in desloratadine levels may potentiate its antihistaminic effects and, more rarely, its cardiac adverse effects such as QT prolongation. Although desloratadine has a low propensity for QT prolongation, the additive serotonergic effects are unlikely, but the interaction is primarily pharmacokinetic, leading to increased exposure and potential dose-related adverse events."
"The coadministration of methadyl acetate and desloratadine may lead to additive QT interval prolongation due to their respective cardiac repolarization effects. Methadyl acetate, as a µ-opioid receptor agonist and known QT-prolonging agent, increases the risk of torsade de pointes and other ventricular arrhythmias. Desloratadine, an antihistamine, possesses weak blocking activity of the hERG potassium channel, which can further potentiate the QT prolongation when combined, resulting in increased risk of life-threatening cardiac arrhythmias, especially in patients with pre-existing risk factors."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR vs DELCOBESE, answered by our medical review team.
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR is a Sympathomimetic that works by Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Pseudoephedrine sulfate is an alpha-adrenergic receptor agonist causing vasoconstriction.. DELCOBESE is a Anorectic (sympathomimetic) that works by Selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking the serotonin transporter (SERT). Additionally, it has a unique property of acting as an agonist at the 5-HT2C receptor, which may contribute to its anorectic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR and DELCOBESE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR is: One tablet (desloratadine 5 mg/pseudoephedrine sulfate 240 mg) orally once daily.. The standard adult dose of DELCOBESE is: Initial dose: 0.5 mg subcutaneously once weekly for 4 weeks, then increase to 1 mg once weekly for 4 weeks, then maintain at 2 mg once weekly. Titrate based on glycemic control up to 2 mg weekly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR and DELCOBESE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR is classified as Category A/B. Desloratadine: no human data, animal studies show no evidence of harm; risk cannot be excluded. Pseudoephedrine: associated with increased risk of gastroschisis in first trimester;. DELCOBESE is classified as Category C. DELCOBESE is contraindicated in pregnancy. First trimester exposure is associated with increased risk of major congenital malformations, particularly neural tube defects, cardiac a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.